Last viewed: ALDX

Prices are updated after-hours

ALDX

Aldeyra Therapeutics, Inc.

ALDX | News | $3.99 0.5% 0.5% 430K

|

Health Technology

(0.0% 1d) (36.3% 1m) (-61.0% 1y) (0.0% 2d) (1.8% 3d) (-4.3% 7d) (Infinity% volume)
Earnings Calendar: 2024-03-07
Market Cap: $ 234,994,114
http://www.aldeyra.com
Sec Filling | Patents | 20 employees

Aldeyra Therapeutics, Inc. operates as a biotechnology company. It primarily focuses on the development of new products for immune-mediated, inflammatory, orphan and other diseases that are thought to be caused in part by naturally occurring toxic chemical species known as free aldehydes. The company was founded by Thomas A. Jordan and John E. Dowling on August 13, 2004 and is headquartered in Lexington, MA.

msa

add to watch list Paper trade email alert is off

Press-releases

Aldeyra Therapeutics to Host Research & Development Day on April 25, 2024
Published: 2024-04-18 (Crawled : 12:00) - biospace.com/
ALDX | News | $3.99 0.5% 0.5% 430K

|

Health Technology

| 1.79% | O: 1.53% H: 2.52% C: 0.25%
day research therapeutics development

Ligand Reports Fourth Quarter and Full Year 2023 Financial Results
Published: 2024-02-27 (Crawled : 13:00) - biospace.com/
TVTX | $5.805 -3.09% -3.19% 970K

|

Health Technology

| -25.31% | O: 2.37% H: 1.46% C: 1.22%
MRK | $125.23 -0.11% 0.0% 6M

|

Health Technology

| -2.69% | O: -0.45% H: 0.7% C: 0.6%
HTGC F | $18.25 0.5% 0.0% 590K

|

| -3.25% | O: -2.77% H: 0.47% C: -0.27%
VKTX | $64.7 -2.66% -2.74% 2.4M

|

Health Technology

| 68.06% | O: 81.31% H: 29.0% C: 21.9%
VRNA | $16.1 -1.83% -1.86% 490K

|

Health Technology

| -8.68% | O: 2.1% H: 2.83% C: -0.5%
LGND | $72.61 -7.94% -8.62% 130K

|

Health Technology

| 5.98% | O: 14.46% H: 11.02% C: 4.72%
ALDX | News | $3.99 0.5% 0.5% 430K

|

Health Technology

| 8.74% | O: 1.91% H: 2.68% C: 1.07%
year financial results

Focal Segmental Glomerulosclerosis Market to Observe Impressive Growth by 2032, Predicts DelveInsight | Leading Companies - ACELYRIN, Genentech, ChemoCentryx, Travere Therapeutics, Boehringer Ingelheim, Chinook Therapeutics
Published: 2024-01-10 (Crawled : 22:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 1.4K

|

Health Technology

| -10.95% | O: 1.1% H: 0.0% C: 0.0%
NVO | $122.75 -1.43% 0.0% 2.8M

|

Health Technology

| 14.59% | O: -0.33% H: 0.35% C: -1.5%
LLY | $745.95 -0.64% -0.1% 1.7M

|

Health Technology

| 19.13% | O: 0.67% H: 0.85% C: 0.21%
SNY | News | $45.395 -1.55% -1.58% 4.4M

|

Health Technology

| -12.45% | O: 0.69% H: 0.0% C: 0.0%
ALDX | News | $3.99 0.5% 0.5% 430K

|

Health Technology

| 19.16% | O: -1.8% H: 0.46% C: -2.44%
companies therapeutics growth market

Aldeyra Therapeutics Provides Clinical and Regulatory Update and Announces Advancement of RASP Platform in Systemic and Retinal Inflammatory Diseases
Published: 2024-01-04 (Crawled : 13:30) - biospace.com/
ALDX | News | $3.99 0.5% 0.5% 430K

|

Health Technology

| 18.81% | O: 0.9% H: 1.18% C: -1.18%
update therapeutics platform

Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from Phase 2 Clinical Trial of ADX-629 in Patients with Atopic Dermatitis
Published: 2023-12-18 (Crawled : 23:00) - biospace.com/
ALDX | News | $3.99 0.5% 0.5% 430K

|

Health Technology

| 31.79% | O: 1.32% H: 3.27% C: -3.27%
adx-629 conference dermatitis trial therapeutics results

Aldeyra Therapeutics Receives Complete Response Letter from the U.S. Food and Drug Administration for the Reproxalap New Drug Application for the Treatment of Dry Eye Disease
Published: 2023-11-27 (Crawled : 23:00) - biospace.com/
ALDX | News | $3.99 0.5% 0.5% 430K

|

Health Technology

| 57.31% | O: -1.19% H: 5.2% C: 4.8%
reproxalap drug disease food treatment eye application therapeutics response

Aldeyra Therapeutics Enters into Exclusive Option Agreement with AbbVie for License to Develop and Commercialize Reproxalap
Published: 2023-11-01 (Crawled : 12:00) - biospace.com/
ABBV | News | $164.66 0.25% -0.15% 4.5M

|

Health Technology

| 16.5% | O: 0.06% H: 1.3% C: 0.43%
ALDX | News | $3.99 0.5% 0.5% 430K

|

Health Technology

| 132.75% | O: 16.96% H: 36.5% C: 27.0%
reproxalap abbvie license therapeutics agreement

NSSC INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Reminds NAPCO Security Technologies, Inc. Investors with Losses to Actively Participate in the Class Action Lawsuit!
Published: 2023-10-25 (Crawled : 22:00) - prnewswire.com
KVUE 4 | $19.58 1.61% -0.36% 11M

|

| -2.33% | O: -4.46% H: 1.49% C: -0.85%
NSSC | $39.76 1.92% 1.89% 250K

|

Producer Manufacturing

| 98.02% | O: -0.81% H: 1.54% C: 0.1%
ALDX | News | $3.99 0.5% 0.5% 430K

|

Health Technology

| 156.77% | O: 0.65% H: 1.92% C: 0.64%
security

APLS NOTICE: ROSEN, A LONGSTANDING AND TRUSTED FIRM, Encourages Apellis Pharmaceuticals, Inc. Investors to Secure Counsel Before Important October 2 Deadline in Securities Class Action - APLS
Published: 2023-09-24 (Crawled : 20:20) - prnewswire.com
ALDX | News | $3.99 0.5% 0.5% 430K

|

Health Technology

| Email alert Add to watchlist
APLS | $47.51 -1.08% -1.09% 1.9M

|

Health Technology

| Email alert Add to watchlist
DFS | $124.27 3.65% -1.02% 2.3M

|

| Email alert Add to watchlist
trusted deadline

ALDX FINAL DEADLINE ALERT: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Aldeyra Therapeutics, Inc. Investors to Secure Counsel Before Important September 29 Deadline in Securities Class Action - ALDX
Published: 2023-09-24 (Crawled : 16:20) - prnewswire.com
ALDX | News | $3.99 0.5% 0.5% 430K

|

Health Technology

| Email alert Add to watchlist
DFS | $124.27 3.65% -1.02% 2.3M

|

| Email alert Add to watchlist
KVUE 4 | $19.58 1.61% -0.36% 11M

|

| Email alert Add to watchlist
deadline

See all

Last 15 days Sec forms

File Id	Form	Published Date	Transaction Date	Direction	Code	Amount Transacted	Owned Amount
0001062993-24-008171	4	2024-04-08	2024-04-05	Buy	P	37712	9275851
0001062993-24-008171	4	2024-04-08	2024-04-04	Buy	P	140281	9238139
0000950170-24-030314	4	2024-03-13	2024-03-09	Buy	A	252280	252280
0000950170-24-030314	4	2024-03-13	2024-03-11	Sell	S	13201	120699
0000950170-24-030311	4	2024-03-13	2024-03-09	Buy	A	405450	405450
0000950170-24-030311	4	2024-03-13	2024-03-12	Sell	S	11537	243495
0000950170-24-030311	4	2024-03-13	2024-03-11	Sell	S	18231	255032

Your Today's Watch List

Sign in to create a watchlist

Gainers vs Losers

64%

36%

Top 10 Gainers

AGBA | News | $1.02 155.0% 57.94% 120M

|

ZCMD | $2.86 108.76% 52.1% 2.3M

|

Commercial Services

INVO | $1.555 104.6% 51.13% 5M

|

Health Technology

ISPC | $0.437 105.16% 49.53% 37M

|

Professional, Scientific, and T...

WLGS | News | $0.92 84.0% 45.65% 1.6M

|

OST | $0.499 21.38% 45.26% 1.9M

|

XPON | News | $3.1 60.62% 37.74% 17M

|

TIRX | $0.7 44.39% 30.74% 58M

|

BNTC | News | $6.92 44.17% 30.64% 3.5M

|

Health Technology

GGE | $0.035 19.86% 29.3% 64M

|

Last 48 Hours Insiders Buying

AXR P 2400 | $22.17 2.69% 0.0% 5.5K

|

| 21:00
QCRH P 118 | $55.405 1.33% 1.31% 54K

|

| 18:01
VUZI P 7500 | $1.26 3.28% 3.17% 1M

|

Electronic Technology

| 18:00
RMCF | $3.61 2.27% 2.22% 18K

|

Consumer Non-Durables

| 20:10

12 months watchlist earnings calendar